Dominique Descamps

TL;DR: The HPV- 16/18 AS04-adjuvanted vaccine showed high efficacy against CIN2+ associated with HPV-16/18 and non-vaccine oncogenic HPV types and substantial overall effect in cohorts that are relevant to universal mass vaccination and catch-up programmes.

TL;DR: End-of-study results show excellent vaccine efficacy against CIN3+ and AIS irrespective of HPV DNA in the lesion, suggesting population-based vaccination that incorporates the HPV-16/18 vaccine and high coverage of early adolescents might have the potential to substantially reduce the incidence of cervical cancer.

TL;DR: Data from the end-of-study analysis of PATRICIA show cross-protective efficacy of the HPV-16/18 vaccine against four oncogenic non-vaccine HPV types-HPV-33, HPV-31, HPV -45, and HPV-51-in different trial cohorts representing diverse groups of women.

TL;DR: Evidence of a significantly reduced survival in patients with neurolisteriosis treated with adjunctive dexamethasone is found, and the time window for fetal losses is determined, which is higher than reported elsewhere.

TL;DR: The findings suggest that HPV vaccination during early adolescence is generally safe, well tolerated, and highly immunogenic, and the implementation of prophylactic HPV vaccination in this age group is supported.